Abstract:The osteophilic and dual‐regulated alendronate‐gene lipoplexes are formulated via a thin‐film dispersion method and electrostatic interaction. The physical barriers are generated by alendronate on the lipoplexes surface, and the genetic signals are produced by antagomir inside the lipoplexes. More notably, alendronate and antagomir‐378a‐3p synergistically regulate osteoclastogenesis and bone resorption through a dual‐driven mechanism, thereby dramatically reversing bone loss. The pathogenesis of postmenopausal osteoporosis (PMOP) is mainly determined by the adhesion of osteoclasts to the bone matrix and the involvement of various molecules in bone resorption. The dual regulation strategy of the physical barriers of bone matrix and intracellular gene regulation generated by advanced biomaterials is a decent alternative for the treatment of PMOP. Herein, for the first time, it is identified that hsa‐miR‐378i/mmu‐miR‐378a‐3p are closely associated with PMOP. Then, an osteophilic and dual‐regulated alendronate‐gene lipoplex (antagomir@Aln‐Lipo), composed of medicative alendronate‐functionalized liposomal vehicle and encapsulated specific microRNAs is engineered, for bone‐targeting delivery of genes to achieve combined mitigation of bone loss. Alendronate targets hydroxyapatite in the bone matrix and occupies the adhesion site of osteoclasts, thus providing the "physical barriers". Antagomir is coupled precisely to specific endogenous microRNAs, thus providing the "genetic signals". These functionalized lipoplexes exhibited long‐term stability and good transfection efficiency. It is proven that antagomir@Aln‐Lipo could synergistically regulate osteoclastogenesis and bone resorption in vitro and in vivo. Furthermore, intravenous injection of antagomir@Aln‐Lipo efficiently reverses bone loss through a dual mechanism driven by alendronate and antagomir‐378a‐3p. In conclusion, the osteophilic and dual‐regulated antagomir@Aln‐Lipo offers a brand‐new bifunctional strategy for the precise treatment of PMOP.

Bone-Targeted Biomimetic Nanogels Re-Establish Osteoblast/Osteoclast Balance to Treat Postmenopausal Osteoporosis

Prussian Blue Nanozyme Normalizes Microenvironment to Delay Osteoporosis

Bone‐Targeting and Multishelled Oral Eldecalcitol Nanoparticles Improve Osteoporosis by Reconstruction of Osteogenic‐Osteoclastic Homeostasis

A Bone Targeting Nanoparticle Loaded Ogp to Restore Bone Homeostasis for Osteoporosis Therapy

Bone-targeting cell membrane-engineered CaCO 3 -based nanoparticles restore local bone homeostasis for microenvironment-responsive osteoporosis treatment

Bone-targeting Cell Membrane-Engineered CaCO3-based Nanoparticles Restore Local Bone Homeostasis for Microenvironment-Responsive Osteoporosis Treatment

Reversing the Imbalance in Bone Homeostasis Via Sustained Release of SIRT-1 Agonist to Promote Bone Healing under Osteoporotic Condition

Inflammatory microenvironment regulation and osteogenesis promotion by bone-targeting calcium and magnesium repletion nanoplatform for osteoporosis therapy

Nanoengineering multifunctional extracellular vesicles availably mitigate bone loss in osteoporosis through binding to RANKL and rebalancing the Treg/Th17 cells

Colon-targeted Engineered Postbiotics Nanoparticles Alleviating Osteoporosis through Gut-Bone Axis

Bone-targeted Bioengineered Bacterial Extracellular Vesicles Delivering Sirna to Ameliorate Osteoporosis

Osteophilic and Dual‐Regulated Alendronate‐Gene Lipoplexes for Reversing Bone Loss

Nanoparticles functionalized with stem cell secretome and CXCR4-overexpressing endothelial membrane for targeted osteoporosis therapy

Synthetic biology‐based bacterial extracellular vesicles displaying BMP‐2 and CXCR4 to ameliorate osteoporosis

Bone-Targeted Supramolecular Nanoagonist Assembled by Accurate Ratiometric Herbal-Derived Therapeutics for Osteoporosis Reversal.

Pueraria lobata-derived exosome-like nanovesicles alleviate osteoporosis by enhacning autophagy

Alendronate Functionalized Bone-Targeting Pomolic Acid Liposomes Restore Bone Homeostasis for Osteoporosis Treatment

Osteoprotegerin gene-modified BMSCs with hydroxyapatite scaffold for treating critical-sized mandibular defects in ovariectomized osteoporotic rats

Injectable double-crosslinked bone cement with enhanced bone adhesion and improved osteoporotic pathophysiological microenvironment for osteoregeneration in osteoporosis

Bone targeting antioxidative nano-iron oxide for treating postmenopausal osteoporosis

Radial Extracorporeal Shock Wave Responsive Precise Nanoplatform for Effective Osteoporosis Sequential Treatment